Universal CAR T-Cell Therapy Helped Treat ALL in Two Infants

Share this content:
Universal CAR T-Cell Therapy Helped Treat ALL in Two Infants
Universal CAR T-Cell Therapy Helped Treat ALL in Two Infants

THURSDAY, Jan. 26, 2017 (HealthDay News) -- Two infants with B-cell acute lymphoblastic leukemia (ALL) are in remission after treatment with genetically modified immune system cells, according to a report on the two cases published in the Jan. 25 issue of Science Translational Medicine.

Waseem Qasim, M.D., Ph.D., a professor of cell and gene therapy at University College London, and colleagues used cells from a healthy donor, then genetically fine-tuned them to be universal chimeric antigen receptor T cells. The cells were altered both to fight the infants' ALL and to minimize the risk of graft-versus-host disease. After receiving the T-cell therapy, one baby did develop graft-versus-host disease. But it was limited to the skin and responded to treatment, according to the study authors.

Both infants went into remission within 28 days of receiving their T-cell infusion. From there, both were able to undergo chemotherapy and a bone marrow transplant. According to Qasim, the babies have remained leukemia-free for 10 and 16 months, and are being closely monitored.

"Having cells premanufactured and ready to use would have obvious advantages in terms of scheduling and coordinating with other treatments," Qasim told HealthDay. Small trials are under way, he added, to see if the therapy can be more widely applied.

Full Text

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

Higher Fish Intake Appears to Reduce RA Symptoms

Higher Fish Intake Appears to Reduce RA Symptoms

Researchers suggest most varieties of fish may play a role in controlling symptoms

Longer Survival for Midostaurin  Chemotherapy in AML With FLT3

Longer Survival for Midostaurin + Chemotherapy in AML ...

Prolonged overall, event-free survival for patients with acute myeloid leukemia, FLT3 mutation

HIV Testing Inadequate in Young Men Who Have Sex With Men

HIV Testing Inadequate in Young Men Who Have ...

Only 28 percent of young MSM have HIV testing, though they account for 83 percent of new diagnoses

is free, fast, and customized just for you!

Already a member?

Sign In Now »